SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genta, Inc. (GNTA)
GNTA 2.290-0.4%11:03 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bob zagorin who wrote (1597)5/31/2002 10:23:48 PM
From: Czechsinthemail  Read Replies (1) of 1870
 
Though potentially very big for Genta, the agreement with Aventis is far from a slam dunk windfall. They receive $50 million in cash and $10 million in convertible debt. Beyond that, the remaining $420 million is contingent upon various milestones. The contingent nature of the agreement keeps uncertainly alive for GNTA shareholders. It may turn out to be a blockbuster deal that richly rewards both Genta and Aventis shareholders. But if Genasense doesn't pan out, the terms of the agreement won't be sufficient to save Genta from a hard fall.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News